Advanced Filters
noise

Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 145 clinical trials
Y Yasemin GEDIKLI, MSc in PT

Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis

The aim of this study was to investigate respiratory muscle sarcopenia in individuals with systemic sclerosis. The main question it aims to answer is: What is the prevalence of respiratory muscle sarcopenia in patients with systemic sclerosis? Participants body composition (bioelectrical impedance), hand grip strength (hand dynanometer), physical performance tests …

18 - 75 years of age All Phase N/A
O Orkun Tüfekçi

Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma

This study aims to investigate the effectiveness of BETY, an exercise approach based on the biopsychosocial model, in children and adults diagnosed with scleroderma.

7 years of age All Phase N/A
J Jing Pan

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)

18 - 60 years of age All Phase 1
O Orkun Tüfekçi

Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance

It is recommended to focus on the physical functionality, chewing, and swallowing performance of individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. The aim was to assess the …

7 years of age All Phase N/A
O Orkun Tüfekçi

Patients Diagnosed With Scleroderma: Physical Performance and Functionality

Physical functionality and performance are important for individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. In light of all this literature, the aim was to evaluate the biopsychosocial …

7 years of age All Phase N/A
D Di Wu

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, …

18 - 70 years of age All Phase N/A

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).

18 - 70 years of age All Phase 1
S Shawna H McIntyre, RN

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

8 - 60 years of age All Phase 2
C Chen Head, MD

Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)

This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease(AID)

18 - 69 years of age All Phase 1
B Benjamin CHAIGNE, MD

Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

The purpose of this study is to determine whether itacitinib is safe and effective in the treatment of systemic sclerosis in adults.

18 years of age All Phase 2

Simplify language using AI